Skip to main content
OpenTrials
Completed

NCT Number: NCT04110886

Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers

This is a A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a kappa receptor agonist HSK21542 in Healthy Volunteers.

The study will enroll approximately 50 adults. The anticipated study duration will be up to 6 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

CMAX Clinical Research Pty Ltd

Adelaide, Australia

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy male and female subjects, age 18-45 years;
  • BMI between 18.0-27.0 kg/m2
  • Determined by investigator to be in general good health according to medical history, comprehensive physical examination;
  • Understanding of the nature, significance, potential benefits and risks of the trial, understanding of the procedures and be able to provide written informed consent voluntarily ;
  • Good communication with investigators, compliance with the study requirements and willingness to stay in phase I clinical trial ward as required.

Exclusion criteria

  • Anyone who has suffered or is currently suffering from any serious diseases, that may interfere with the results of the trial;
  • Determined by investigator to be abnormal with clinical significance in Physical examination, vital signs monitoring, electrocardiogram, chest radiograph, laboratory examination;
  • HBsAg positive, HCV antibody positive, Treponema pallidum antibody positive, or HIV antibody positive;
  • QTcF > 450ms;
  • Allergic constitution;
  • Intolerance of venipuncture and/or history of haemorrhage or needle fainting;
  • Drug or alcohol abuse;
  • Have used any prescription, over-the-counter, Chinese herbal medicine or health products within 14 days;
  • Blood donation or massive bleeding within 3 months (greater than 450 mL);
  • Participants in any drug clinical trial within 3 months.
  • Birth planning in the next six months.

Treatment and study plan

HSK21542

Drug

Single dose, injection, starting dose of 0.2ug escalating up to 20ug

Placebo

Drug

Single dose, injection matching placebo

Primary outcomes

  1. Number of subjects with adverse events

    Time frame: Between screening and 7-9 days after dosing

    To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of adverse events

  2. Number of subjects with abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters

    Time frame: Between screening and 7-9 days after dosing

    To evaluate the safety and tolerability of HSK21542 in comparison with placebo after a single injection in healthy subjects in terms of abnormal physical examination/ abnormal vital signs/ abnormal laboratory parameters

Secondary outcomes

  1. Cmax

    Time frame: From the start of administration to 24 hours after administration

    Maximum (peak) plasma drug concentration

  2. Tmax

    Time frame: From the start of administration to 24 hours after administration

    Time to reach maximum (peak) plasma concentration following drug administration

  3. t1/2

    Time frame: From the start of administration to 24 hours after administration

    Elimination half-life

  4. AUC0-t

    Time frame: From the start of administration to 24 hours after administration

    Area under the plasma concentration-time curve from time zero to time t.

  5. AUC0-inf

    Time frame: From the start of administration to 24 hours after administration

    Area under the plasma concentration-time curve from time zero to infinity

  6. CL

    Time frame: From the start of administration to 24 hours after administration

    Apparent total body clearance of the drug from plasma

  7. Vd

    Time frame: From the start of administration to 24 hours after administration

    Apparent volume of distribution

Sponsors and collaborators

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of a Kappa Receptor Agonist HSK21542 in Healthy Volunteers

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Oct 1, 2019
Registry last updated
Feb 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.